ArticleMedical journal, Armed Forces India
Expression of
Article in Medical journal, Armed Forces India. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood leukemia with high mortality rate. In 2016 revision of ALL, WHO suggested role of Cytokine Receptor-like Factor 2 (CRLF2) gene overexpression in disease biology. Hence, it is imperative to study the role of CRLF2 gene overexpression with survival outcome. Methods: The present study is a cross sectional prospective analytical study. Children (1-14 years) with B lineage acute lymphoblastic leukemia (B-ALL) were recruited for the study. Children with cardiac disease, endocrine disease, autoimmune disease, any other malignancy, any progressive neurological disease or who have received prior treatment for B-ALL were excluded from the study. CRLF2 overexpression was seen using reverse transcriptase real time PCR while copy number alterations in the pseudoautosomal region (PAR1) genes (CRLF2, CSF2RA, IL3RA) were detected using multiplex ligation-dependent probe amplification (MLPA). Results: Total 93 children with B-ALL were evaluated for CRLF2 gene expression. The CRLF2 gene expression was found to be overexpressed in 8 (8.6 %) of the children. Eight out of 14 patients with CRLF2 overexpression had duplication of CRLF2 gene with/without accompanying IL3RA, CSF3RA or P2RY8 gene alterations. CRLF2 overexpression was associated with deletions of CSF2RA, IL3RA and/or P2RY8 genes and extra copies of CRLF2 gene. However, CRLF2 gene overexpression was not found to be significantly associated with any of the clinical parameters, response to treatment parameters or survival outcome. Conclusions: CRLF2 gene is overexpressed in those with IL3RA, CSF2RA and P2RY8 gene deletions. However, CRLF2 overexpression is not associated with survival outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.